Dow Agrosciences LLC

Incyte Corporation

W. L. Gore & Associates, Inc.

Incyte Holdings Corporation

Corteva Agriscience LLC

Pfizer Corporation

Rinat Neuroscience Corporation

Akzo Nobel Chemicals International B.v.

Interface Biologics, Inc.

Mei Li

Holger Tank

Lei Liu

Stephen L Wilson

Robert L Cleek

Kuide Qin

Jiacheng Zhou

Yongchun Pan

Paul D Drumheller

Hong Zhang

David George Ouse

James David Rodgers

Pingli Liu

Hui Shao

David J Meloni

Brian Walter Metcalf

Tai-Yuen Yue

Edward H Cully

Stacey Shepard

Argyrios George Arvanitis

Michael Xia

Qiyan Lin

Martin Charles Logan

Jaume Pons

Carey V Campbell

Benjamin M Trapp

Haisheng Wang

Raymond E Boucher, Jr

Thomas G Triebes

Theresa A Holland

Karin Leontein

Donna Marie Stone

Per Antoni

Michael J Vonesh

Cody L Hartman

Richard L Dunn

Zhongjiang Jia

Charles David Claude

Thane L Kranzler

Yongzhong Wu

Shili Chen

Shawn Zhu

James Michael Gifford

Brandon Matthew Downer

Vishwas Madhav Paralkar

Frank M Nedza

Laurine G Galya

Adam Shilling

Joseph C Hercamp

Hao Shen

Franklin N Keeney

Bruce M Steinhaus

Franklin Nelson Keeney

Peter D Traylor

Paul C Begovac

Mingxing Zhou

Hiteshkumar Dave

Richard W Korsmeyer

Paul Christopher Begovac

Dennis George Wujek

Jinxia Susan Sun

William L Rocco

Derek J Hopkins

Peter Heicksen

Robert Matthew Buttimor

Alex Williams

James F Davidson

Greg Powels

Dan Wu

Scott A Jeffers

Melissa Gail Olds

Alex Kennedy

F Nelson Keeney

Tanvi Mitesh Shah

Roy Biran

Lorenzo Aulisa

Francis Dumont

Ying Liu

Huifang Wu

Daniel L Crandall

Gregory LoStracco

Nora Mardirosian

Nicola Stagg

T Craig Blewett

James M Gifford

Marco Antonio Tavares Do Nascimento

Melissa Olds

T Blewett

Frank J Laronde

Franklin Keeney

David Meloni

Scott Alexander Jeffers

Richard Lee Dunn

Richard Wilker Korsmeyer

Tc Blewett

Raymond E Boucher

The present disclosure is directed toward composite materials comprising high aspect ratio habits of drug crystals which can be partially or fully extending into a substrate, and additionally, can be projecting from a substrate at an angle of about 20° to about 90°. The present disclosure is directed toward medical devices, such as medical balloons, comprising said composite and methods of using and making the same. The described composite can be used for the local treatment of vascular disease. The present disclosure is also directed toward paclitaxel crystals with a hollow acicular habit.

Porous composites with high-aspect ratio crystals

Spray drift during the application of an aqueous mixture of glyphosate and an auxinic herbicide is reduced by incorporating certain tertiary amine or tertiary amine oxide surfactants into the aqueous solution or mixture to be sprayed.

Amine and amine oxide surfactants for controlling herbicide spray drift

The present invention is related to processes for preparing a composition comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine utilizing chiral acids.

Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine

The present invention relates to crystalline forms of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3'-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2&#x2032;-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, including methods of preparation thereof, and related synthetic intermediates, where the compound is useful in the treatment of various diseases including infectious diseases and cancer.

Crystalline form of a PD-1/PD-L1 inhibitor

The present disclosure is directed to injectable formulations that include biodegradable polymers based on trimethylene carbonate (TMC) with mole fractions of polylactic acid (PLA) and/or polyglycolic acid (PGA) that are used to deliver a bioactive agent to a targeted site. Excipients such as polyethylene glycol (PEG) may be added to the formulations to reduce the injection force and/or to modulate the release of the bioactive agent. Suitable biodegradable polymers for use in the injectable formulations include D,L-PLA:TMC, D-PLA:TMC, L-PLA:TMC, TMC:PLA:PGA and variations thereof. Additionally, copolymers of TMC and PLA and terpolymers of TMC:PLA:PGA may be formed into nanoparticles and delivered to the target site with an injectable crosslinkable polyethylene glycol system. In at least one embodiment, the injectable formulations are used to treat ocular diseases.

Injectable and biodegradable polymer formulations for controlled release of bioactive agents

The mixture of certain amine salts of glyphosate and 2,4-D allows the preparation of high-strength liquid compositions containing up to greater than 450 gae/L of total active ingredient loading if the pH is adjusted to about 6.0 to about 8.0. Compositions are particularly well-suited for application to crops that are resistant or tolerant to both glyphosate and 2,4-D.

High-strength, herbicidal compositions of glyphosate and 2,4-D salts

According to the invention there is provided inter alia a medical device for delivering a paclitaxel to a tissue, the device the device having a coating layer applied to a surface of the device, the coating layer comprising components i), ii) and iii), wherein component i) is a therapeutic agent which is paclitaxel; and component ii) is urea or a pharmaceutically acceptable salt thereof, or a urea derivative or a pharmaceutically acceptable salt thereof; and component iii) is succinic acid, glutaric acid or caffeine, or a pharmaceutically acceptable salt of any one thereof.

Drug composition and coating

Spray drift during the application of agricultural chemicals is reduced by incorporating a self-emulsifiable ester into the liquid to be sprayed.

Controlling spray drift of pesticides with self-emulsifiable esters

The present disclosure is directed toward composite materials comprising high aspect ratio habits of drug crystals which can be partially or fully extending into a substrate, and additionally, can be projecting from a substrate at an angle of about 20&#xb0; to about 90&#xb0;. The present disclosure is directed toward medical devices, such as medical balloons, comprising said composite and methods of using and making the same. The described composite can be used for the local treatment of vascular disease. The present disclosure is also directed toward paclitaxel crystals with a hollow acicular habit.

Novel high-strength herbicidal oil-in-water emulsions containing a water soluble salt of glyphosate and an oil soluble herbicide active ingredient show enhanced stability to oil phase coalescence and active ingredient crystallization by the use of specific surfactants and water immiscible organic solvents.

Stable high strength oil-in-water emulsions

The present invention relates to an improved nitrification inhibitor composition and its use in agricultural applications.

Microencapsulated nitrification inhibitor compositions

According to the invention there is provided inter alia a medical device for delivering a paclitaxel to a tissue, the device the device having a coating layer applied to a surface of the device, the coating layer comprising components i), ii) and iii), wherein

The invention is directed to delivery medical devices that enable consistent 'on-demand' delivery of therapeutic agents to a vessel. The medical device of the current invention comprises retractable sheath comprising neckable elements. The medical device of the current invention comprises an expandable member, a hydrophilic coating comprising at least one therapeutic agent about the expandable member or structural layer and a retractable outer sheath with a selectively permeable microstructure. The design and methods disclosed herein ensures that therapeutic agent delivery occurs essentially only during retraction of the outer sheath, minimizing coating and/or therapeutic agent loss to the bloodstream and providing controlled delivery to the treatment site.

Retractable sheath devices, systems, and methods

The present application relates to pharmaceutical formulations and dosage forms of a lysine specific demethylase-1 (LSD1) inhibitor, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, including methods of preparation thereof, which are useful in the treatment of LSD1 mediated diseases such as cancer.

Formulations of an LSD1 inhibitor

The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases. 

Processes for preparing pyrazolyl-substituted pyrrolo[2,3-d]pyrimidines

Growing community of inventors

Westfield, IN, United States of America

Mei Li